Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2024 Nov 14:52:102136.
doi: 10.1016/j.rmcr.2024.102136. eCollection 2024.

Erythema nodosum followed by eosinophilic pneumonia as an adverse effect of dupilumab treatment in a patient with severe asthma

Agnieszka Gawlewicz-Mroczka  1 , Marek Przybyszowski  1 , Grażyna Bochenek  1 , Maria Mroczka  2 , Krzysztof Sładek  1
Affiliations
Case Reports

Erythema nodosum followed by eosinophilic pneumonia as an adverse effect of dupilumab treatment in a patient with severe asthma

Agnieszka Gawlewicz-Mroczka et al. Respir Med Case Rep. .

Abstract

Dupilumab is a monoclonal antibody that has recently been introduced for the treatment of asthma. It has the potential to significantly alter the progression and severity of T2 -dependent diseases, including severe asthma. However, dupilumab can cause transient hypereosinophilia. In rare cases, hypereosinophilia can reach high levels and manifest with clinical symptoms. We present the case of a female patient who presented with hypereosinophilia of almost 5000 cells/μL accompanied by erythema nodosum during dupilumab treatment. After stopping and then restarting dupilumab, the patient developed eosinophilic pneumonia. This case highlights the need to monitor blood eosinophil count along with clinical and radiological symptoms in patients receiving dupilumab.

Keywords: Asthma; Biologics; Dupilumab; Eosinophilia; Erythema nodosum.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Figures

Fig. 1
Fig. 1
Chest HRCT revealing ground-glass opacities.
See this image and copyright information in PMC

References

    1. Menzella F., Montanari G., Patricelli G., Cavazza A., Galeone C., Ruggiero P., et al. A case of chronic eosinophilic pneumonia in a patient treated with dupilumab. Therapeut. Clin. Risk Manag. 2019;15:869–875. - PMC - PubMed
    1. Nishiyama Y., Koya T., Nagano K., Abe S., Kimura Y., Shima K., et al. Two cases of dupilumab-associated eosinophilic pneumonia in asthma with eosinophilic chronic rhinosinusitis: IL-5-driven pathology? Allergol. Int. 2022;71:548–551. - PubMed
    1. Nishida K., Takaaki N., Shiori T., Satsuki I., Yasuhiro T., Gakuya T., et al. A case of eosinophilic pneumonia in a patient receiving dupilumab therapy. J. Japan Soc. Respi. Endos. 2022;4:377–382.
    1. Kurihara M., Masaki K., Matsuyama E., Fujioka M., Hayashi R., Tomiyasu S., et al. How can dupilumab cause eosinophilic pneumonia? Biomolecules. 2022;12:1743. - PMC - PubMed
    1. Mustin D.E., Cole E.F., Blalock T.W., Kuruvilla M.E., Stoff B.K., Feldman R.J. J Dupilumab-induced erythema nodosum. JAAD Case Rep. 2021 Nov 17;19:41–43. - PMC - PubMed

Publication types

LinkOut - more resources